Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$24.90Cboe Real-Time Last Sale as of 2:20PM ET 10/15/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.69(2.85%)
Bid (Size)$24.84 (100)
Ask (Size)$24.95 (100)
Day Low / High$24.23 - 25.06
Volume473.6 K

Aimmune Therapeutics Presents New Data From Follow-On Study of AR101 for Peanut Allergy

8:12AM ET 6/04/2019 MT Newswires
Aimmune Therapeutics (AIMT) said Tuesday that new data from a follow-on study of its peanut allergy drug AR101 showed that extending daily therapy with AR101 for an additional 28 weeks resulted in improved tolerability with lower numbers of adverse events, an increase in the amount of peanut that could be safely ingested and continued immunomodulation to peanut protein in most patients.

The data were presented on Tuesday in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2019 in Lisbon.

AR101 is an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts.

The majority of the patients enrolled in the follow-on study could tolerate doses of at least 1,000 mg of peanut protein after they continued daily doses of AR101 for a further 28 weeks, and almost half of all AR101-treated patients tolerated the highest 2,000 mg dose during the exit food challenge. In addition, the patients experienced significant immunological changes, the company said.

Price: 19.96, Change: +0.39, Percent Change: +1.99